Related references
Note: Only part of the references are listed.Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group
Carlos Solano et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
Jan Styczynski et al.
BONE MARROW TRANSPLANTATION (2020)
Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study
Isabella Martin et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes
Carlos Solano et al.
BONE MARROW TRANSPLANTATION (2019)
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
Per Ljungman et al.
LANCET INFECTIOUS DISEASES (2019)
Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis
Estela Gimenez et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2019)
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
F. M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients
Carlos Solano et al.
TRANSPLANT INFECTIOUS DISEASE (2017)
Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood
C. Solano et al.
BONE MARROW TRANSPLANTATION (2016)
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
Pierre Teira et al.
BLOOD (2016)
Would Kinetic Analyses of Plasma Cytomegalovirus DNA Load Help to Reach Consensus Criteria for Triggering the Initiation of Preemptive Antiviral Therapy in Transplant Recipients?
Victor Vinuesa et al.
CLINICAL INFECTIOUS DISEASES (2016)
Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
Margaret L. Green et al.
LANCET HAEMATOLOGY (2016)
Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients
David Navarro et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
How I assess comorbidities before hematopoietic cell transplantation
Mohamed L. Sorror
BLOOD (2013)
Estimating Cytomegalovirus Growth Rates by Using Only a Single Point
Deborah Cromer et al.
JOURNAL OF VIROLOGY (2013)
Dynamics of Cytomegalovirus (CMV) Plasma DNAemia in Initial and Recurrent Episodes of Active CMV Infection in the Allogeneic Stem Cell Transplantation Setting: Implications for Designing Preemptive Antiviral Therapy Strategies
Beatriz Munoz-Cobo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Definitions of cytomegalovirus infection and disease in transplant recipients
P Ljungman et al.
CLINICAL INFECTIOUS DISEASES (2002)
Share Paper
